ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01654939
Recruitment Status : Withdrawn
First Posted : August 1, 2012
Last Update Posted : September 28, 2015
Sponsor:
Collaborator:
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Douglas T. Dieterich, Icahn School of Medicine at Mount Sinai

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : September 2014
  Estimated Study Completion Date : September 2015